[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100629901":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":11,"centralContacts":15,"locations":10,"responsibleParty":20,"collaborators":10,"id":23,"slug":24,"hasResults":25,"nctId":26,"briefTitle":27,"officialTitle":28,"acronym":10,"eligibilityCriteria":29,"healthyVolunteers":25,"sex":30,"minAge":31,"maxAge":10,"enrollmentInfo":32,"targetDuration":35,"studyType":36,"phases":10,"briefSummary":37,"conditions":38,"keywords":40,"overallStatus":42,"whyStopped":10,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":10},{"fullName":5,"class":6},"Fudan University","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":10},"advanced HER2-negative breast cancer patients previously treated with ADC",null,[12],{"name":13,"affiliation":5,"role":14},"Jian Zhang","PRINCIPAL_INVESTIGATOR",[16],{"name":13,"role":17,"phone":18,"phoneExt":10,"email":19},"CONTACT","64175590","syner2000@163.com",{"type":14,"investigatorFullName":21,"investigatorTitle":22,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Jian Zhang,MD","Professor","100629901","eribulin-mesylate-based-therapy-in-patients-with-advanced-her2-negative-breast-cancer-previously-treated-with-adc-100629901",false,"NCT07480694","Eribulin Mesylate-based Therapy in Patients With Advanced HER2-negative Breast Cancer Previously Treated With ADC","Real-world Study of Eribulin Mesylate-based Therapy in Patients With Advanced HER2-negative Breast Cancer Previously Treated With Antibody-drug Conjugates","Inclusion Criteria:\n\n1. At least 18 years old;\n2. Inoperable locally advanced or metastatic breast cancer;\n3. Planning to use a single-agent or combination treatment regimen based on eribulin;\n4. HER2 negative (IHC 0,+, or ++ but ISH negative);\n5. Previously received ADC treatment at the local advanced or metastatic disease stage;\n6. Previously received chemotherapy (including ADC) for local advanced or metastatic disease no more than 2 lines, where one treatment line is defined as completing at least one cycle of chemotherapy;\n7. Eastern Cooperative Oncology Group (ECOG) performance status score (PS) 0-2;\n8. The investigators have evaluated that the patient's organ and bone marrow functions are suitable for medication use and there are no relevant contraindications;\n9. The subjects voluntarily join the study and sign the informed consent.\n\nExclusion Criteria:\n\n1. HER2-positive tumors\n2. The hormone receptor status is unknown;\n3. Patients who have received eribulin treatment before;\n4. Those who have had other malignant tumors within the past 5 years (excluding the following situations: cured skin basal cell carcinoma, cervical carcinoma in situ, papillary thyroid carcinoma; second primary cancer that has been cured and has no recurrence within 5 years; subjects who have clearly identified the origin of the metastatic lesion as being from a certain primary tumor);\n5. Mental illness or mental disorder, patients with poor compliance and inability to cooperate and describe treatment responses;\n6. Pregnant or lactating women;\n7. Other serious or uncontrollable diseases, or other conditions assessed by the researcher as not suitable for enrollment.","ALL","18 Years",{"count":33,"type":34},400,"ESTIMATED","12 Months","OBSERVATIONAL","This study is a real-world study. we collected patients with advanced HER2-negative breast cancer previously treated with antibody-drug conjugates, and received eribulin mesylate-based therapy post-ADC. We retrospectively collect the data on previous systemic treatment, and prospectively collect the treatment data of the therapeutic regimens based on eribulin mesylate.",[39],"Treatment Efficacy",[41],"Eribulin Mesylate-based Therapy, Advanced HER2-negative Breast Cancer, ADC","NOT_YET_RECRUITING","2026-03-14",{"date":45,"type":46},"2026-03-18","ACTUAL",{"date":48,"type":34},"2026-03",{"date":50,"type":34},"2028-02",{"name":5,"class":6}]